Amphastar Pharmaceuticals Reports Net Revenues of $56.9 Million for the First Quarter Ended March 31, 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Amphastar Pharmaceuticals Reports Net Revenues of $56.9 Million for the First Quarter Ended March 31, 2015
May 14, 2015 10:27 AM EDT
Jefferies maintains a Buy rating on Amphastar Pharmaceuticals (NASDAQ: AMPH), and raised the price target to $19.00 (from $18.00), after a strong Q1. Analyst David Steinberg said that the strong Q1 was driven by a better than expected top line.
Steinberg commented on AMPH, saying, "Posting sales of $27.1M (+37% Y/Y), AMPHs base IMS injectables business contributed to half of the Q1 rev upside relative to our est, largely reflecting price... More
May 13, 2015 6:01 AM EDT
Amphastar Pharma (NASDAQ: AMPH) reported Q1 EPS of ($0.01), versus $0.00 reported last year. Revenue for the quarter came in at $56.89 million, versus $45.87 million reported last year.
For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.
...
More
